Key Takeaways
- • RoC tripled global retail sales from approximately $100 million in 2018 to $300 million by 2024, while simultaneously delivering 21 consecutive quarters of market share gains and reclaiming the No. 1 position in U.S. eye cream, according to NielsenIQ data.
- • The brand achieved more than double EBITDA margin expansion and secured an estimated $500 million exit to new ownership, demonstrating margin-accretive growth in a competitive mass skincare category.
- • RoC's transformation under private equity ownership succeeded not through brand reinvention or aggressive product line expansion, but through disciplined focus on core equity, deliberate strategic sequencing, and construction of an aligned leadership team.
- • Founded in 1957 by French pharmacist Jean-Charles Lissarrague, RoC's competitive advantage rested on decades of dermatological rigor and clinical credibility in stabilized retinol—equity that remained intact during its period as a smaller asset within a large healthcare conglomerate prior to 2019 divestiture.
Summary
RoC's six-year transformation from a marginalized heritage brand to a private equity-driven growth engine represents a disciplined case study in brand reactivation within the competitive mass skincare market. In 2018, RoC operated as a profitable but subordinated asset within one of the world's largest healthcare conglomerates, where portfolio prioritization had diminished its market prominence despite the brand's intact scientific credibility. Following divestiture in 2019, the brand entered private equity ownership at a strategic crossroads.
The turnaround executed between 2019 and 2024 produced measurable results across all key metrics. Global retail sales tripled from approximately $100 million to $300 million. Market share performance showed consistent strength: RoC delivered 21 consecutive quarters of market share gains and restored its position as the No. 1 eye cream brand in the United States, according to market research firm NielsenIQ. EBITDA margins more than doubled, indicating that growth was controlled and accretive to profitability rather than revenue-driven at the expense of margins. The asset ultimately achieved an estimated $500 million exit to new ownership, representing significant value creation.
Critically, RoC's strategy diverged from conventional brand revitalization playbooks. The transformation did not rely on aesthetic reinvention, celebrity partnerships, or aggressive product line extension—tactics common in contemporary beauty marketing. Instead, management executed disciplined focus on the brand's core positioning: dermatological rigor and clinical efficacy, particularly in retinol innovation. RoC's original equity, established since its 1957 founding by French pharmacist Jean-Charles Lissarrague, centered on scientific credibility rather than marketing narrative. The private equity ownership model aligned stakeholder incentives around intensifying this existing positioning rather than attempting wholesale repositioning.
The operational execution required construction of a leadership team capable of executing both strategic focus and operational scaling. The transformation underscores that reactivation of dormant brand equity within large conglomerates can generate significant returns when paired with aligned ownership, clear strategic direction, and disciplined operational discipline—a thesis of particular relevance to institutional investors evaluating portfolio company potential within healthcare-adjacent consumer categories.
The turnaround executed between 2019 and 2024 produced measurable results across all key metrics. Global retail sales tripled from approximately $100 million to $300 million. Market share performance showed consistent strength: RoC delivered 21 consecutive quarters of market share gains and restored its position as the No. 1 eye cream brand in the United States, according to market research firm NielsenIQ. EBITDA margins more than doubled, indicating that growth was controlled and accretive to profitability rather than revenue-driven at the expense of margins. The asset ultimately achieved an estimated $500 million exit to new ownership, representing significant value creation.
Critically, RoC's strategy diverged from conventional brand revitalization playbooks. The transformation did not rely on aesthetic reinvention, celebrity partnerships, or aggressive product line extension—tactics common in contemporary beauty marketing. Instead, management executed disciplined focus on the brand's core positioning: dermatological rigor and clinical efficacy, particularly in retinol innovation. RoC's original equity, established since its 1957 founding by French pharmacist Jean-Charles Lissarrague, centered on scientific credibility rather than marketing narrative. The private equity ownership model aligned stakeholder incentives around intensifying this existing positioning rather than attempting wholesale repositioning.
The operational execution required construction of a leadership team capable of executing both strategic focus and operational scaling. The transformation underscores that reactivation of dormant brand equity within large conglomerates can generate significant returns when paired with aligned ownership, clear strategic direction, and disciplined operational discipline—a thesis of particular relevance to institutional investors evaluating portfolio company potential within healthcare-adjacent consumer categories.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.